Source: Accentia Biopharmaceuticals, Inc.
Article Date: 03 March 2007 - 10:00 PST
Summary:
In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune--a patent-pending pharmaceutical treatment in late-stage development for a variety of autoimmune diseases--improves function in most patients and stops progression in over 90% of cases refractory to standard therapies. Developed by researchers at the Johns Hopkins University School of Medicine, Revimmune works by temporarily eliminating peripheral immune cells, including the immune cells causing the autoimmunity, while selectively sparing the stem cells in the bone marrow.
